Serology


Last updated: 2021 Sep 4
Total hit(s): 53
Select item(s)
Key Findings
Comments
(You can add your comments too!)
Original Article
(hover to see details)
Seroprevalence of anti-SARS-CoV-2 antibodies in children at 2 different time points was assessed. The antibody levels were significantly lower in the first time point (13th to 29th May 2020) compared to the second time point (24th October to 23rd November 2020). Neutralisation assay showed that the low titre values in asymptomatic children were not protective in the first time point. In the first time point,all seropositive children were asymptomatic (titre <8) at the time of anti-SARS-CoV-2 testing. In the second time point, 7/26 children were found to be positive for SARS-CoV-2 by RT-PCR. 69.2% children in the second time point with titre >8 were asymptomatic.
33927556
(Biochem Med (Zagreb))
PMID
33927556
Date of Publishing: 2021 Jun 15
Title Seroprevalence of SARS-CoV-2 infection among children in Children's Hospital Zagreb during the initial and second wave of COVID-19 pandemic in Croatia
Author(s) nameLenicek Krleza J, Zrinski Topic R et al.
Journal Biochem Med (Zagreb)
Impact factor
2.26
Citation count: 1
Date of Entry 2021 Sep 4


SARS-CoV-2 specific IgM antibodies were detected using colloidal gold immunochromatographic assay (GICA). The assay was positive for 82.2% (37/45) of RT-PCR positive cases and 32% (8/25) of RT-PCR negative. The GICA can be a useful test to compliment the existing PCR-based assay for confirmation of COVID-19.
32476607
(Emerg Microbes Infect)
PMID
32476607
Date of Publishing: 2020 Dec
Title Delayed specific IgM antibody responses observed among COVID-19 patients with severe progrssion
Author(s) nameShen L, Wang C et al.
Journal Emerg Microbes Infect
Impact factor
5.84
Citation count: 13
Date of Entry 2021 Sep 4


Sequential serum samples collected from SARS-CoV-2 infected individuals showed a seroconversion of >95%. Neutralising antibodies response is typical of a viral infection with a decline in antibody titres after a peak. A higher viral load may lead to more severe disease and generate a stronger antibody response through increased levels of viral antigen. Vaccine Boosters may be required to provide long-lasting protection and also from reinfection.
33106674
(Nat Microbiol)
PMID
33106674
Date of Publishing: 2020 Dec
Title Longitudinal observation and decline of neutralizing antibody responses in the three months following SARS-CoV-2 infection in humans
Author(s) nameSeow J, Graham C et al.
Journal Nat Microbiol
Impact factor
27.9
Citation count: 42
Date of Entry 2021 Sep 4


In COVID-19 patients, the patterns of IgG and IgM antibody response were studied. The IgM antibody response began and peaked earlier than the IgG antibody response. The IgM antibody response decreased three weeks after the illness, but the IgG antibody response remained constant. COVID-19 patients with severe illness had a more vigorous IgM and IgG antibody response.
32515684
(Emerg Microbes Infect)
PMID
32515684
Date of Publishing: 2020 Dec
Title Patterns of IgG and IgM antibody response in COVID-19 patients
Author(s) nameLiu X, Wang J et al.
Journal Emerg Microbes Infect
Impact factor
5.84
Citation count: 18
Date of Entry 2021 Sep 4


Anti-SARS-CoV-2 IgM antibody response (against nucleoprotein) was significantly lower in the mildly ill patients when compared to severely ill patients. IgG responses (against nucleoprotein) were detected 9 days after disease onset in both mild and severely ill patients. Neutralising antibody response was detectable 10 days after onset in both sets of patients. In patients with MERS, antibodies that cross-react with SARS-CoV and SARS-CoV-2 were detected. Detectin of SARS-CoV-2 specific IgG in the urine and sputum could be used as a potential marker to detemine disease severity. No antibodies were detectable in the fecal samples. Monitoring S and N antibody levels could be used to determine neutralisng titers before convalescent plasma transfusion.
32634129
(J Clin Invest)
PMID
32634129
Date of Publishing: 2020 Oct 1
Title Kinetics of viral load and antibody response in relation to COVID-19 severity
Author(s) nameWang Y, Zhang L et al.
Journal J Clin Invest
Impact factor
10.51
Citation count: 33
Date of Entry 2021 Sep 4


Chemiluminescent microparticle immunoassay (CMIA) was used to measure the IgG antibodies against SARS-CoV-2 nucleocapsid protein (NCP) and a lab-developed proteome array was used to detect IgM against NCP. There was no significant difference in the IgG antibody levels between the patients with mild/moderate SARS-CoV-2 infection and those with severe disease. Although the IgG assay had 100% specificity, antibody levels cannot be used to predict disease severity.
32666092
(Am J Clin Pathol)
PMID
32666092
Date of Publishing: 2020 Sep 8
Title SARS-CoV-2 Antibody Responses Do Not Predict COVID-19 Disease Severity
Author(s) namePhipps WS, SoRelle JA et al.
Journal Am J Clin Pathol
Impact factor
2.03
Citation count: 8
Date of Entry 2021 Sep 4


An estimation of the seroprevalence against SARS-CoV-2 in a random sample of health care workers in a hospital in Spain was assesed . At the peak of the COVID-19 epidemic, very low seroprevalence of 9.3% was reported.
32641730
(Nat Commun)
PMID
32641730
Date of Publishing: 2020 Jul 8
Title Seroprevalence of antibodies against SARS-CoV-2 among health care workers in a large Spanish reference hospital
Author(s) nameGarcia-Basteiro AL, Moncunill G et al.
Journal Nat Commun
Impact factor
11.8
Citation count: 37
Date of Entry 2021 Sep 4


The SARS-CoV-2 specific neutralising antibodies were assessed in COVID-19 patients with mild disease. The neutralising antibody titers correlated with the spike binding antibodies that target the S1, receptor binding domain (RBD) and S2. A positive correlation was observed between the neutralising antibody titers and plasma CRP levels(r=0.5) and a negative correlation with the lymphocyte counts (r=-0.44).
32346091
(Nat Rev Immunol)
PMID
32346091
Date of Publishing: 2020 Jun
Title Neutralizing antibody response in mild COVID-19
Author(s) name van der Heide V.
Journal Nat Rev Immunol
Impact factor
41.65
Citation count: 2
Date of Entry 2021 Sep 4


Antibody levels against the anti-SARS-COV-2 nucleoprotein and Receptor binding domain (RBD) were assessed in COVID-19 patients. The anti-nucleoprotein and RBD IgG antibody levels correlated with neutralising antibody titers. The viral load in the saliva of patients was highest during the first week of infection. The median viral load in the oropharangeal saliva was 52 log10 copies per mL. Viral RNA was detected 25 days after symptom onset in one patient. Older age correlated with higher viral load.
32213337
(Lancet Infect Dis)
PMID
32213337
Date of Publishing: 2020 May
Title Temporal profiles of viral load in posterior oropharyngeal saliva samples and serum antibody responses during infection by SARS-CoV-2: an observational cohort study
Author(s) nameTo KK, Tsang OT et al.
Journal Lancet Infect Dis
Impact factor
21.77
Citation count: 715
Date of Entry 2021 Sep 4


In the acute phase of the disease, the virus-specific IgG levels were significantly lower in the asymptomatic individuals when compared to symptomatic individuals. In the early convalescent phase, 40% of the asymptomatic and 12.9% of the symptomatic group became seronegative respectively. The pro-and anti-inflammatory cytokine levels were lower in the asymptomatic group when compared to the symptomatic group.
32555424
(Nat Med)
PMID
32555424
Date of Publishing: 2020 Aug
Title Clinical and immunological assessment of asymptomatic SARS-CoV-2 infections
Author(s) nameLong QX, Tang XJ et al.
Journal Nat Med
Impact factor
22.66
Citation count: 327
Date of Entry 2021 Jul 24


The antibody dynamics in COVID-19 patients were assessed. The seroconversion rates for Ab, IgM and IgG was found to be 98.8%, 93.8% and 93.8% respectively. The median seroconversion time post-symptom onset was 9,10 or 12 days for Ab, IgM and IgG respectively. The seroconversion time post-exposure was 15, 18 and 20 days for Ab, IgM and IgG respectively. Limitation of this study includes: (1) only symptomatic infections were enrolled, (2) most blood samples were collected at 1 month post-onset, so the duration of antibodies cannot be estimated, (3) the antibody levels were not exactly titrated, and different antigens were used in total antibody (RBD), IgM (RBD) and IgG (Nucleoprotein), (4) no blood sample was collected during the incubation period. Three different antibody tests-ELISA, CMIA and LFIA were used. No significant difference was observed between the ELISA and other forms of immunoassays.
32430429
(Eur Respir J)
PMID
32430429
Date of Publishing: 2020 Aug
Title Serology characteristics of SARS-CoV-2 infection since exposure and post symptom onset
Author(s) nameLou B, Li TD et al.
Journal Eur Respir J
Impact factor
7.8
Citation count: 80
Date of Entry 2021 Jul 24


Receptor binding domain (RBD)-specific IgG antibodies are detected in all hospitalised COVID-19 patients 6 days after PCR confirmation. Class switching is dominated by RBD-specific IgG1 and IgG3 responses. The IgG antibody titres positively correlated with neutralising antibody responses. The RBD-specific IgG ELISA assay is highly sensitive and specific and can be used as a surrogate of neutralisation activity against SARS-CoV-2 infection.
32835303
(Cell Rep Med)
PMID
32835303
Date of Publishing: 2020 Jun 23
Title Rapid Generation of Neutralizing Antibody Responses in COVID-19 Patients
Author(s) nameSuthar MS, Zimmerman MG et al.
Journal Cell Rep Med
Impact factor
Cant find
Citation count: 50
Date of Entry 2021 Jul 24


A serosurvey in a Los Angeles county showed the prevalence of antibodies (either IgG or IgM) was 4.65% (unweighted prevalance was 4.34%). 13% reported fever with cough, 9% reported fever with shortness of breath and 6% reported loss of smell or taste.
32421144
(JAMA)
PMID
32421144
Date of Publishing: 2020 Jun 16
Title Seroprevalence of SARS-CoV-2- Spedefic Antibodies Among Adults in Los Angeles County, California, on April 10-11,2020
Author(s) nameSood N, Simon P et al.
Journal JAMA
Impact factor
14.78
Citation count: 75
Date of Entry 2021 Jul 24


Children with severe COVID-19 develop a weak and delayed anti-SARS-CoV2. Amongst the sero-positive children, the IgG antibody levels against the spike protein were higher in convalescent and multistem inflammatory syndrome in children (MIS-C) when compared to children with acute infection. No differences were found in the IgM levels amongst different cohorts. Low levels of circulating T follicular helper (cTfh) cells and high plasma concentration of inflammatory cytokines was associated with poor antibody responses.
-
()
PMID
-
Title A Poor and Delayed Anti-SARS-CoV2 IgG Response is Associated to Severe COVID-19 in Children
Date of Entry 2021 Jul 24


In-vitro neutralization assays revealed that Israeli strain containing the P681H mutation was not associated with higher infection rates and got neutralized by sera from vaccinated individuals. Cell lines were infected with Isolates: Israeli P681H strain (isolate hCoV-19/Israel/CVL-45176-P681H-ngs/2020), (b) non-P681H strain from Israel (isolate hCoV-19/Israel/CVL-45526-ngs/2020) and (c) B.1.1.7 strain (isolate hCoV-19/Israel/CVL-46879-ngs/2020)
Pre-print (medRXiv)
Date of Publishing 2021 Mar 25
Title A unique SARS-CoV-2 spike protein P681H strain detected in Israel
Author(s) nameNeta S. Zuckerman, Shay Fleishon et al.
Date of Entry 2021 Jun 14


This study reports that one-third of the outpatients in Nicaragua had an acute mild COVID-19 infection and these patients were found to be seropositive for up to six months.
Pre-print (medRXiv)
Date of Publishing -
Title Antibody response to SARS-CoV-2 infection over six months among Nicaraguan 2 outpatients
Author(s) name -
Date of Entry 2021 Jun 14


In a serology study, SARS-CoV-2 binding IgG and neutralising antibodies were detectable for up to one year in PCR-confirmed SARS-CoV-2 positive participants. The magnitude and durability of neutralising antibodies correlated positively with disease severity. NA
Pre-print (medRXiv)
Date of Publishing -
Title SARS-CoV-2 antibodies remain detectable 12 months after infection and antibody magnitude is associated with age and COVID-19 severity
Author(s) name -
Date of Entry 2021 Jun 14


In a small number of COVID-19 patients with mild disease, most of them showed antibodies against SECD, S1, RBD, and N for each isotype. The healthy individuals did not show these antibodies.
33450669
(Virology)
PMID
33450669
Date of Publishing: 2021 Jan 6
Title Incomplete humoral response including neutralizing antibodies in asymptomatic to mild COVID-19 patients in Japan
Author(s) nameTakeshita M, Nishina N et al.
Journal Virology
Impact factor
2.819
Citation count: 1


In a serology study, the presence of IgG and IgM antibody response in symptomatic and asymptomatic patients was assessed. The results showed that within 7 days at least 35% of the candidates showed seroconversion and within 45 days of symptoms onset, 95% showed simultaneous or sequential detection of IgM and IgG.
33444413
(PLoS Pathog)
PMID
33444413
Date of Publishing: 2021 Jan
Title Emergency response for evaluating SARS-CoV-2 immune status, seroprevalence and convalescent plasma in Argentina
Author(s) nameOjeda DS, Gonzalez Lopez Ledesma MM et al.
Journal PLoS Pathog
Impact factor
6.18
Citation count: 1


A SARS-CoV-2 serology study conducted in a group of healthcare workers including nurses and non-patient-facing administrators showed a seropositivity prevalence of 4.8%. The serological study amongst healthcare workers in the Chicago area showed highest case rates were in the Southwest and Northwest Side neighborhoods and lower case rates on the North Side and Near-North suburbs.
33447642
(Open Forum Infect Dis)
PMID
33447642
Date of Publishing: 2021 Jan
Title Seroprevalence and Correlates of SARS-CoV-2 Antibodies in Health Care Workers in Chicago
Author(s) nameWilkins JT, Gray EL et al.
Journal Open Forum Infect Dis
Impact factor
2.69
Citation count: 1


A considerable heterogeneity of IgM kinetics was observed in a longitudinal study of antibody response in COVID-19 patients.
33444413
(PLoS Pathog)
PMID
33444413
Date of Publishing: 2021 Jan
Title Emergency response for evaluating SARS-CoV-2 immune status, seroprevalence and convalescent plasma in Argentina
Author(s) nameOjeda DS, Gonzalez Lopez Ledesma MM et al.
Journal PLoS Pathog
Impact factor
6.18
Citation count: 1


The presence of anti-SARS-CoV-2 antibodies in a small number of symptomatic and asymptomatic Tyrolian cohort was assessed. Stable antibody response with good neutralising activity was detectable for upto 6 months. The total Ig against for RBD and IgG agianst S1 spike protein was measured.
33315138
(Wien Klin Wochenschr)
PMID
33315138
Date of Publishing: 2020 Dec 9
Title 6-month SARS-CoV-2 antibody persistency in a Tyrolian COVID-19 cohort
Author(s) nameDeisenhammer F, Borena W et al.
Journal Wien Klin Wochenschr
Impact factor
1.15
Citation count: 1


In a small group of 29 people who had recovered from COVID-19, persistent antibody response against SARS-CoV-2 was observed upto 6 months after infection. Blood collected at time point T1 (mean of 72 weeks) and all 29 participants at time point T2 (mean of 142 weeks), and time point T3 (mean of 271 weeks).
33315138
(Wien Klin Wochenschr)
PMID
33315138
Date of Publishing: 2020 Dec 9
Title 6-month SARS-CoV-2 antibody persistency in a Tyrolian COVID-19 cohort
Author(s) nameDeisenhammer F, Borena W et al.
Journal Wien Klin Wochenschr
Impact factor
1.15
Citation count: 1


This serosurveillance research on 3296 industrial workers showed that 7.37% of people had SARS-C0V-2 IgG. A rapid decline in the protective IgG antibodies was observed 45-65 days after the initial test.
33282604
(Cureus)
PMID
33282604
Date of Publishing: 2020 Dec 2
Title A Prospective Study on Rapidly Declining SARS-CoV-2 IgG Antibodies Within One to Three Months of Testing IgG Positive: Can It Lead to Potential Reinfections?
Author(s) nameNag DS, Chaudhry R et al.
Journal Cureus
Impact factor
Cant find
Citation count: 1


The presence of anti-SARS-CoV-2 IgG antibody response in pregnant women was studied. The seroprevalence at the time of delivery is low.
33310133
(J Gynecol Obstet Hum Reprod)
PMID
33310133
Date of Publishing: 2020 Dec 10
Title SARS-COV-2 IgG antibody response in pregnant women at delivery
Author(s) nameTsatsaris V, Mariaggi AA et al.
Journal J Gynecol Obstet Hum Reprod
Citation count 1